Table 1.
Summary of studies reporting on post-SIRT hypertrophy after unilobar SIRT
| Paper | Number of patients | Age | Pathology treated | SIRT modality | Site of Y90 delivery | Number of treatment sessions | Method of volume measurement | Time to measurement | Percentage hypertrophy (mean/median (range)) |
|---|---|---|---|---|---|---|---|---|---|
| Ahmadzadehfar et al. 2013 Germany13 |
24 | Median 53 (range 44–78) | Metastatic disease (mixed) 17 – bi-lobar |
Resin microspheres | Right lobe | Single | FDG PET/CT | Mean 44 days, median 36 days | Mean 47%, median 34% Only right lobe disease – mean 57%, median 70% |
| Edeline et al. 2013 France14 |
34 | Not stated | Primary – HCC | 30 Glass, 4 resin microspheres | 23 right, 11 left | Single | CT | 3 months Not stated |
Mean 29% Mean 42% (maximal) |
| Vouche et al. 2013 USA15 |
83 | Median 68 (range 36–89) | 67 HCC, 8 IHC, 8 CRC mets | Glass microspheres | Right lobe | Single | MRI/CT | 1- >9 months | Median overall 26% (−14–86) Median 45% at 9 months (5–186) |
| Theysohn et al. 2013 Germany16 |
45 | Mean 71.9 | HCC | Glass microspheres | Right lobe | Single | CT | 6 Months | Mean 30.8% |
| Fernandez-Ros et al. 2013 Spain17 |
83 | Median 66 | 52 HCC, 4 IHC, 13 CRC mets, 14 others | Resin microspheres | 66 right, 17 left | Single | CT/MRI | 26 weeks | Mean 45% |
| Garlipp et al. 2013 Germany, France18 |
26 | Mean 59.2 | Metastatic disease (mixed) | Resin microspheres | Right lobe | Single | MRI | Median 46 days (27–79 days) | Mean 29%, median 25.3% |
| Teo et al. 2014 Singapore19 |
17 | Median 72 (range 42–78) | HCC | Resin microspheres | Right lobe | Single | CT | Median 5 months | Mean 34.2% |
HCC, hepatocellular carcinoma; IHC, intrahepatic cholangiocarcinoma; CRC mets, colorectal cancer metastases; FDG PET, fluorodeoxyglucose positron-emission-tomography; CT, computed tomography; MRI, magnetic resonance imaging.